GlassScriptPhysician profile
Amanda Dailey Crowe
NPI 1073723383
$831.56
in general payments reported to CMS, 2019-2025
14 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.01 · 2022: $33.21 · 2023: $259 · 2024: $348 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $205.85 | 2022-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $161.46 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Procept Biorobotics Corporation | $88.29 | 2024-2025 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $66.33 | 2024 | Provenge |
| Novartis Pharmaceuticals Corporation | $51.46 | 2024-2025 | |
| Roche Diagnostics Corporation | $47.31 | 2019-2023 | Benchmark Ultra |
| Myriad Genetic Laboratories, INC. | $40.07 | 2022-2023 | Prolaris |
| Sumitomo Pharma America, INC. | $35.90 | 2023-2024 | Orgovyx |
| Janssen Biotech, INC. | $32.42 | 2024-2025 | Erleada, Akeega, Balversa |
| Eisai INC. | $32.36 | 2023-2024 | |
| Exelixis INC. | $19.41 | 2023 | Cabometyx |
| Genzyme Corporation | $18.00 | 2023 | |
| Coloplast Corp | $17.60 | 2019 | |
| Becton, Dickinson and Company | $15.10 | 2025 | Arista |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.